A new study entitled “Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users” published in JAMA Surgery calls into question the current guidelines advising doctors to pause a widely used class of diabetes drugs—sodium-glucose cotransporter 2 inhibitors (SGLT2i) — before surgery. The findings suggest the risk of developing postoperative euglycemic ketoacidosis (eKA), a serious and potentially...
A new study in The Journal of Clinical Endocrinology & Metabolism has revealed that Black/African Americans are significantly more likely to develop severe insulin-deficient diabetes (SIDD), a more serious form of the disease, compared to White Americans. Using data-driven cluster analysis, a technique widely used within the field of artificial intelligence (AI) and Machine Learning,...
Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 diabetes, regardless of body mass index (BMI) and other traditional risk factors, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Yo-yo dieting is defined...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating...
Recent studies shed light on the safety and efficacy of diabetes medications GLP-1 receptor agonists, SGLT2 inhibitors, and DPP4 inhibitors were all scrutinized in new research presented at ENDO 2024. While most of the results were good news for the impact of medications for people with type 2 diabetes, clinicians prescribing these medications should be...
New research explores the impact of prediabetes on a Mexican population. According to a study presented at ENDO 2024, prediabetes increases the risk of dying before the age of 75, particularly due to heart disease, kidney disease, and acute diabetic complications in Mexican populations. The study’s author, Carlos A. Fermín-Martínez, MD, discusses his findings and...
As online ads abound for diabetes and obesity medications, endocrinologists should be prepared to talk to patients who may be attracted to GLP-1 drug lookalikes and supplements from questionable sources. GLP-1 agonists are a cultural phenomenon. Celebrities and social media influencers hyping the drugs’ weight-loss success has led to demand outstripping supply, resulting in shortages...
The Endocrine Society’s 2025 Fred Conrad Koch Lifetime Achievement Award recipient, Daniel Drucker, MD, first discovered his passion for science in high school when he learned “this is how stuff works.” He’s still learning to this day, and he tells Endocrine News about his ongoing scientific quests, the mentors who made a difference along the...
The Endocrine Society’s 2025 Fred Conrad Koch Lifetime Achievement Award recipient, Daniel Drucker, MD, first discovered his passion for science in high school when he learned “this is how stuff works.” He’s still learning to this day, and he tells Endocrine News about his ongoing scientific quests, the mentors who made a difference along the...
